Background. The comparative effects of aspirin and F(ab')2 fragments of monoclonal antibody 7E3 against the platelet glycoprotein lIb/llla receptor on ex vivo platelet aggregation and in vivo thrombosis were studied in a canine coronary balloon angioplasty model. Methods and Results. Three groups were studied. Group 1 (n = 8) was pretreated with saline placebo, group 2 (n =8) was pretreated with 325 mg aspirin, and group 3 (n =8) was pretreated with 0.8 mg/kg 7E3 F(ab')2. Coronary angioplasty was performed in the left anterior descending coronary artery of open-chest dogs under fluoroscopic control; serial measurements of basal and hyperemic coronary blood flows were then made for 2 hours after application of an external stenosis that decreased hyperemic flow by 50%. There were no significant differences in platelet counts or hemodynamic measurements during the experiments. Platelet aggregation was decreased by treatment: group 1, 64±13% versus 50±13% (p=NS); group 2, 57±4% versus 25±4% (p<0.001); and group 3, 77±5% versus 10±6% (p<0.0002). Compared with initial measurements, the 7E3 antibody was superior to aspirin in maintaining hyperemic coronary blood flow after release of the external stenosis: group 1, 177±14 versus 21±14 ml/min (p<0.0003); group 2, 189+9 versus 110±28 ml/min (p<0.008); and group 3, 194±12 versus 181±15 ml/min (p<0.02). In group 1, arterial occlusion developed in five dogs, and nonocclusive thrombus was seen in three dogs. In group 2, arterial occlusion developed in one dog, and nonocclusive thrombus was seen in five dogs. No thrombotic material was visualized in group 3 dogs treated with 7E3 F(ab')2.
Conclusions. In this animal model, the 7E3 antiplatelet antibody is superior to aspirin in inhibiting platelet aggregation, thrombosis, and acute closure after deep arterial injury caused by coronary balloon angioplasty. (Circulation 1991; 84:2463 -2469 A cute closure during percutaneous transluminal coronary angioplasty is the most serious procedural complication limiting more widespread use of this nonsurgical alternative to revascularize atherosclerotic coronary arteries. The reported incidence of acute closure is 2-8%,'-9 but it may be higher in centers where more complex lesions are being approached. Topol10 has estimated that persistent acute closure occurred in at least 10,000 patients in 1987, resulting in more than 6,000 emergency coronary bypass graft surgeries and more than 1,000 deaths. An unknown number of additional patients had impending or temporary acute closure that responded to nonsurgical interventions. The most common pathophysiological event precipitating acute closure is a complex intimal tear with subsequent thrombus formation. 2, 4411, 12 Arterial injury initiates platelet activation and thrombin production, which can result in the formation of a platelet-rich occlusive thrombus.13,14 Platelet activation is mediated by one of three pathways through the action of either collagen and thrombin or ADP and serotonin or arachidonic acid.14 Aspirin reduces but does not prevent the acute thrombotic complications associated with coronary angioplasty15-20 by inhibiting the arachidonic acid pathway and decreasing platelet aggregation. A more potent agent that completely prevented platelet aggregation could eliminate the risk of acute thrombosis in coronary angioplasty. 13 The final common pathway resulting in platelet aggregation involves cross-linking platelets by binding fibrinogen and other adhesive glycoproteins (GPs) to the GP lIb/llla receptor complex on the platelet surface membrane. 13 King , N.C.) was placed proximally on the artery, and an elastic band was placed distal to the flow probe so that blood flow could be intermittently interrupted. A high-fidelity micromanometer catheter (Millar Instruments, Houston, Tex.) was passed through the apex of the heart into the left ventricular cavity to measure systolic blood pressure, left ventricular end-diastolic pressure, and the first derivative of left ventricular pressure (dP/dt). Protocol Twenty-four dogs were randomized to one of three intravenous treatment groups: group 1, saline placebo; group 2, 325 mg aspirin; and group 3, 0.8 mg/kg antibody 7E3 F(ab')2.3'5 The production of antibody 7E3 F(ab')2 (Centocor, Inc., Malvern, Pa.) has been described.21'2227 Blood for platelet count and platelet aggregation studies was withdrawn from the internal jugular sheath as described below. Continuous recordings of heart rate, systolic arterial pressure, left ventricular end-diastolic pressure, dP/dt, and LAD blood flow were obtained with an eight-channel physiological recorder (model 2800S, Gould Electronics, Cleveland, Ohio). Three to five measurements of basal coronary blood flow and hyperemic coronary blood flow after a 20-second occlusion were made in the LAD. Treatment was then administered by intravenous injection. Thirty minutes after treatment, an 8F Amplatz angioplasty guiding catheter (USCI, Billerica, Mass.) was inserted through the arterial sheath and positioned in the left main coronary artery. A 4.0x20 mm balloon angioplasty catheter (USCI) was then advanced into the LAD under fluoroscopic control until the balloon was just distal to the flow probe. Arterial injury was accomplished by inflating the oversized balloon twice for 60 seconds at 10 atm with 60 seconds between the inflations. After the catheters were withdrawn, a rigid C clamp was applied to the artery and adjusted to create a stenosis that decreased hyperemic blood flow by 50%. Repeat hemodynamic and blood flow measurements were made every 15 minutes for 2 hours. Arterial occlusion was determined by the absence of blood flow as measured by the electromagnetic flow probe. The C clamp was released after 2 hours, and repeat measurements were made. Blood for platelet count and aggregation studies was again withdrawn. Finally, 400 mg of Evans blue dye dissolved in 20 mg of isotonic saline was injected intravenously. Five minutes later, the dog was killed by injecting 20 mg potassium chloride i.v., and the heart was extirpated. The LAD was then longitudinally opened and inspected for macroscopic intravascular thrombus formation. The arterial lumen was flushed clean and inspected for blue staining to confirm arterial injury.30 '3' Platelet Studies Blood (20 ml) was withdrawn from the internal jugular cannula into a plastic syringe containing 3.2% sodium citrate as the anticoagulant (1:10 citrate! blood, vol:vol) at baseline and 2 hours after treatment. The platelet count was determined with a Haema Count MK-4/HC system (J.T. Baker, Allentown, Pa.). Platelet-rich plasma (PRP), the supernatant present after centrifuging anticoagulated whole blood at 1,000 rpm for 5 minutes (140g), was diluted with platelet-poor plasma (PPP) to achieve a platelet 
Platelet Studies
Treatment with aspirin or antibody 7E3 did not significantly change the platelet count during the experiment (Figure 1 ). Platelet aggregation in the control group decreased insignificantly from 64+13% to 50±13% (Figure 2 acute closure, myocardial infarction, and the need for emergency bypass graft surgery. [15] [16] [17] [18] [19] [20] This experimental model successfully demonstrated the same phenomenon. The importance of adequate heparin dosage to decrease fibrin accumulation and platelet deposition after arterial injury has been recently reemphasized.48,49 Heparin was not used in this study, but it was not effective in preventing platelet activation and hyperemic coronary blood flow changes in a similar model. 43 Pharmacological interventions available to treat acute thrombus formation in the clinical setting include augmenting heparin50 and administering thrombolytic therapy,51 but they frequently are inadequate in quickly restoring blood flow. A number of mechanical alternatives to emergency surgery have been developed that can stabilize the artery.52 However, preventing acute closure rather than developing new treatment strategies for it would be more clinically desirable. Although new thrombin antagonists5354 may have use in this situation, platelet-directed therapy seems more reasonable since platelet-rich thrombi have been implicated in causing acute closure. 13 The 7E3 monoclonal antibody appears to be superior to aspirin as an antiplatelet agent. Yasuda et a127 demonstrated that 7E3 F(ab')2 prevents thrombosis in a sub-total occlusion model, whereas aspirin does not. 55 Coller et a124 showed that the ability of 7E3 F(ab')2 to prevent cyclic flow reductions in the Folts model47 of acute platelet thrombus formation is not reversed by epinephrine infusion, as occurs after aspirin inhibition. The present study shows that 7E3 F(ab')2 is superior to aspirin in decreasing ex vivo platelet aggregation and in vivo thrombus formation after balloon arterial injury. Unfortunately, electron microscopy was not performed to confirm that vascular injury was similar in the three groups and to verify that platelet deposition was reduced in animals treated with the antibody.
The 7E3 F(ab')2 antibody is easy to administer, inhibits platelet aggregation for more than 24 hours, and has not caused serious bleeding in this or previous studies.22'24-28 However, bleeding risk will need to be carefully evaluated in clinical trials in which administration of heparin will probably be used.
Results from the present study confirm previous research24,25,28,29 demonstrating that hemodynamic values and platelet counts are not perturbed by 7E3 F(ab')2. Immunogenicity is minimal56 and has been further reduced in subsequent research by using the Fab fragment instead of the F(ab')2 fragment of the 7E3 immunoglobulin, potentially allowing repeat future administration of murine antibodies in many patients. The ability of 7E3 to prevent acute plateletmediated thrombosis suggests several possible clinical applications. First, 7E3 could be more successful than aspirin in preventing the acute complications associated with unstable angina pectoris and non-Q wave myocardial infarction. Second, preliminary evidence suggests that 7E3 F(ab')2 can facilitate thrombolysis and prevent reocclusion, 26 
